cancerresearch

Cancer Research

2 Years ago

Method to 'turn off' mutated melanoma: New study provides novel insights into the pathogenesis and treatment of NRAS mutant melanoma

Melanoma is the deadliest form of skin cancer and notorious for its resistance to conventional chemotherapy. Approximately 25 percent of melanoma is driven by oncogenic mutations in the NRAS gene, making it a very attractive therapeutic target. However, despite decades of research, no effective therapies targeting NRAS have been forthcoming.

  • 0 Likes

  • 0 Comments

See posts by others with similar interest